Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages 986-996

  Hills, Robert K ^a   Castaigne, Sylvie ^b   Appelbaum, Frederick R ^c   Delaunay, Jacques ^d   Petersdorf, Stephen ^c   Othus, Megan ^c   Estey, Elihu H ^c   Dombret, Hervé ^e   Chevret, Sylvie ^b   Ifrah, Norbert ^f   Cahn, Jean Yves ^g   Récher, Christian ^h   Chilton, Lucy ⁱ   Moorman, Anthony V ⁱ   Burnett, Alan K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c Fred Hutchinson Cancer Research Center   (United States)

^d HÔTEL DIEU   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CYTOGENETICS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INDUCTION CHEMOTHERAPY; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; REMISSION; RISK; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONFIDENCE INTERVALS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84905560676     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70281-5     Document Type: Article

References (27)

1. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001, 7:1490-1496.
2. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002, 16:1627-1636.
3. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001, 92:406-413.
4. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003, 102:4277-4283.
5. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011, 29:369-377.
6. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012, 30:3924-3931.
7. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013, 121:4854-4860.
8. Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation: results of the GOELAMS AML 2006 IR study. Blood (ASH annual meeting abstracts) 2011, 118. abstr 79.
9. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the ALFA group. Leukemia 2007, 21:66-71.
10. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin conjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalisation by leukemic and normal myeloid cells. Blood 2001, 97:3197-3204.
11. Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379:1508-1516. for the Acute Leukemia French Association.
12. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
13. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
14. Treatment of early breast cancer, volume 1: worldwide evidence 1985-1990 1990, Early Breast Cancer Trialists' Collaborative Group, Oxford University Press, Oxford.
15. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
16. Kharfan-Dabaja MA, Hamadani M, Reljic T, et al. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013, 163:315-325.
17. Li X, Xu SN, Qin DB, et al. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Ann Oncol 2014, 25:455-461.
18. Amadori S, Suciu S, Salih H, et al. The sequential combination of gemtuzumab ozogamicin and intensive chemotherapy does not benefit older patients with untreated AML: results of the EORTC-GIMEMA AML-17 randomized trial. Haematologica 2012, 97(suppl 1):446. (abstr 1091D).
19. Brunnberg U, Mohr M, Noppeny R, et al. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol 2012, 23:990-996.
20. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose ara-C improves remission rate but does not significantly prolong survival: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013, 27:75-81.
21. Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013, 31:4123-4131.
22. Borthakur G, Faderl S, Verstovsek S, et al. Molecular response in core binding factor acute myelogenous leukemia with fludarabine, cytarabine, G-CSF and gemtuzumab ozogamicin. Blood (ASH annual meeting abstracts) 2008, 112. abstr 1937.
23. Lambert J, Lambert J, Nibourel O, et al. Minimal residual disease assessed by WT1 expression and NPM1 mutations specific RQ-PCR assays identifies patients with distinct outcomes in the ALFA 0701 trial and is decreased by treatment with gemtuzumab ozogamicin. Blood (ASH annual meeting abstracts) 2012, 120. abstr 659.
24. Lazenby M, Gilkes AF, Marrin C, et al. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 2014, published online Feb 27. 10.1038/leu.2014.90.
25. Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2012, 16:1699-1704.
26. Glamis AS, Aplenc R, Alonzo TA, et al. Gemtuzumab ozogamicin (GO) in children with de novo acute myeloid leukemia (AML) improves event-free survival (EFS) by reducing relapse risk-results from the randomized phase III Children's Oncology Group (COG) trial, AAML0531. Blood 2013, 122:355.
27. Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: time to resurrect?. J Clin Oncol 2012, 30:3921-3923.